Picard Medical Q1 revenue up 85%, gross margin 24%; NYSE listing notice received

Picard Medical, Inc.

Q1 2026 revenue $1.2M (+85% YoY); gross profit margin 24% vs. -58% in Q1 2025.
2025 total revenue $4.9M (+12.5%); IPO raised $17.4M net; year-end cash $11.5M.
Repaid $7.4M senior debt in Q1; post-quarter public offering raised $5.0M gross.
Next-gen Emperor TAH second-gen animal testing completed May 2026; FDA submission target 2028.
NYSE American notified of stockholders' equity deficiency; compliance plan due June 7, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.